A Agilent Technologies Inc.

Agilent Presents Solutions Innovation Research Awards to Aarhus University, University of Graz, and Imperial College London Scientists

(NYSE: A) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of , Professor Walter Gössler of , and Professor Gregory Offer of . These separate awards recognize their outstanding contributions to battery research.

Developing new materials for more efficient and durable batteries is essential to reducing fossil fuel reliance and meeting global energy storage needs. Given the limited supply of critical metals like lithium, it is crucial to focus on pioneering new materials and recovering and reusing existing metals. This dual approach sustains current battery production and minimizes environmental impact, supporting a more sustainable future.

Professor Anders Bentien at Aarhus University focuses on battery research using atomic spectroscopy measurement technologies. As part of his award, Professor Bentien will receive a one-year loan of an to support his projects. He envisions this system as crucial for the kinetic and thermodynamic description of the flow battery systems he is working on. Upon receiving the award, Professor Bentien remarked, “We are very happy to have the possibility to utilize the ICP-OES instrument and see its capabilities.”

Professor Walter Gössler’s research at the University of Graz is dedicated to transforming lithium-ion battery recycling. His project focuses on enhancing recycling efficiency, reducing environmental impact, and ensuring sustainability of lithium-ion battery recycling. As part of his initiative, Professor Gössler will receive a one-year loan of an , which will be instrumental in achieving these goals.

Discussing the award, Professor Gössler said, “The University of Graz is honored to receive the Agilent ICP-MS 8900 QQQ instrument through the Solutions Innovation Research Award. This support enables us to enhance our recycling processes and push the boundaries of innovation in battery recycling. We are excited to leverage this technology to drive our sustainable solutions forward.”

Professor Gregory Offer at Imperial College London is advancing battery research using gas chromatography/mass spectrometry (GC/MS) technologies. His work addresses gas generation and battery volume swelling, key issues in lithium-ion battery performance degradation. While most studies focus on fresh cells, Professor Offer emphasizes the importance of understanding degradation in end-of-life cells. He will receive a one-year loan of an to support his research.

Speaking about the award Professor Offer stated, “Dr. Jingwen Weng, my postdoctoral fellow, and I are very excited to accept the Agilent SIRA award and receive the GC/MS for a year. We intend to use the equipment to study lithium-ion batteries in order to improve our understanding of their formation, degradation during use, and failure. Analyzing the gases produced at different stages of life will give us critical information about the chemical reactions that happen inside the batteries, and help us to parameterize and validate our physics-based models. These models can then be used by industry to design safer, cheaper, and longer-lasting battery packs.”

Commenting on the importance of these awards Nahid Chalyavi, associate vice president of University Relations and External Research at Agilent said, “At Agilent, we are proud to support researchers who are addressing some of the most pressing challenges in energy storage and battery technology. The work of Professors Bentien, Gössler, and Offer represents the kind of innovative, forward-thinking research that drives meaningful progress toward a more sustainable future. By equipping them with cutting-edge analytical tools, we aim to empower their efforts to unlock new insights, improve battery efficiency, and reduce environmental impact. The outcomes of their research have the potential to not only advance scientific understanding but also deliver practical solutions that can be adopted by industry to create safer, more efficient, and longer-lasting energy storage systems.”

Agilent is committed to driving research growth in battery, fuel cell, and semiconductor technologies within the advanced materials and energy markets. Established in 2023, the Agilent SIRA program, part of the Agilent University Relations, inspires innovative and impactful applications of Agilent products to help solve pressing scientific problems in academia. By providing state-of-the-art products and technical expertise, Agilent supports university researchers across diverse fields of study. For more information about the program, visit .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on and .

EN
13/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch